1S1 Stock Overview
A biotechnology company, discover and develops treatments for serious and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.40 |
| 52 Week High | US$23.40 |
| 52 Week Low | US$10.50 |
| Beta | 1.11 |
| 11 Month Change | -16.36% |
| 3 Month Change | 36.30% |
| 1 Year Change | 29.58% |
| 33 Year Change | 8.88% |
| 5 Year Change | 91.67% |
| Change since IPO | -90.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1S1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.7% | 0.8% | -0.4% |
| 1Y | 29.6% | -16.7% | 7.1% |
Return vs Industry: 1S1 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 1S1 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 1S1 volatility | |
|---|---|
| 1S1 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1S1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1S1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 94 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| 1S1 fundamental statistics | |
|---|---|
| Market cap | €1.50b |
| Earnings (TTM) | -€245.26m |
| Revenue (TTM) | €288.11k |
5,146x
P/S Ratio-6.0x
P/E RatioIs 1S1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1S1 income statement (TTM) | |
|---|---|
| Revenue | US$302.00k |
| Cost of Revenue | US$159.77m |
| Gross Profit | -US$159.46m |
| Other Expenses | US$97.62m |
| Earnings | -US$257.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | -52,802.32% |
| Net Profit Margin | -85,127.15% |
| Debt/Equity Ratio | 2.9% |
How did 1S1 perform over the long term?
See historical performance and comparison